



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

NEW SCIENTIFIC PUBLICATION FURTHER SUPPORTS BIOMARK'S ASSAY

Vancouver, British Columbia – (August 27th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Predictive value and clinical significance of increased SSAT-1 activity in healthy adults” has been published in the peer-reviewed journal *Future Science OA*.

Rashid Ahmed, President and CEO, says, “This is our latest trilogy SSAT-1(Spermidine/spermine N¹-acetyltransferase) publication and we would like to acknowledge the contributions made by a dedicated team of clinicians, scientists and researchers. This publication provides additional scientific validation and evidence that one of our technology platforms (SSAT1 assay) has important clinical applications in the cancer diagnostic space. In our previous clinical studies, we observed that some healthy volunteers (“outliers”) had, higher than expected acetylated amantadine (AA) concentration. This was intriguing and we subsequently conducted detailed clinical assessments. Analysis of the ‘outliers’ observed in previous studies using the amantadine test revealed that a large number were at risk or developed cancer, suggesting that the test can predict the occurrence of cancer. Monitoring of urinary AA concentration combined with clinical and hematological characteristics could be established as a useful tool for purposes of screening and follow-up for cancer in high-risk populations. Our findings in ‘outliers’ support usefulness of amantadine assay as a screening or surveillance test in populations considered at high risk for developing cancer. It is also possible that this test could be used for monitoring patients after curative surgical or chemoradiation therapy to assess eradication of the tumor. Also, in follow-up, it could possibly detect proliferation of new cancer cells (relapse)”.

“We are on track to publish additional peer reviewed papers and present abstracts or posters in the near term on significant discoveries that we have strategically invested resources over the past few years.” says Rashid.

The paper is available through open access at <https://www.future-science.com/doi/full/10.2144/fsoa-2019-0023> and on <https://www.ncbi.nlm.nih.gov/pubmed/31428447>. BioMark encourages subscription to Future Science for individuals and institutions interested in keeping abreast of new developments in biotechnology and medicine.

About Future Science OA

Launched in March 2015, Future Science OA is the inaugural gold open access journal from Future Science Group. It publishes articles covering research of application to human health and utilizes a CC-BY license. Future Science OA embraces the importance of publishing all good-quality research with the potential to further the progress of medical science. Negative and early-phase research will be considered. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis.

About Future Science Group

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. Both publish eBooks and journals. In addition to this core publishing business FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine. The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.

For all queries, contact Laura Dormer email to: l.dormer@futuremedicine.com>

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website <https://thecse.com/>.

For further information on BioMark, please Contact:

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

Tel. 604-370-0779

Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Biomark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.